Neurologist Dr. Leah Croll reports on the first ever blood test approved by the Food and Drug Administration, giving the test ...

Strategies aimed at reducing dementia risk usually target those around 40 to 60 years of age. We should start earlier and make prevention a lifelong goal, say these researchers.

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

There are 164,000 people in Virginia age 65 and older who suffer from Alzheimer’s, according to the Alzheimer’s association.

And that could heighten your chances of developing Alzheimer's disease. A study published by the Multidisciplinary Digital Publishing Institute (MDPI) suggests that the seemingly harmless act of ...

Alzheimer's Advocacy Day came as the number of Americans ... "The goal is to find the disease fast, get treatment and put you on a path to treatment and a better life," Addison said.

As Alzheimer’s disease now affects seven million Americans — the largest number ever — there is a growing demand for new treatments. Scientists at the University of California, Irvine ...

“As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer’s disease,” said Luca Passamonti, MD ...

For the first time, the number of Americans living with Alzheimer’s disease (AD) has surpassed 7 million, according to the Alzheimer’s Disease Facts and Figures report released this week.

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in ...

Metabolic syndrome was associated with a 24% increased risk for young-onset dementia, defined as dementia before the age of 65 years, with stronger associations found in women vs men, younger vs ...